Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis April 1, 2025
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial February 20, 2025
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor July 25, 2024
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D March 18, 2024
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea September 20, 2023
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D July 7, 2022
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH October 20, 2021
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH September 8, 2021
Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH October 12, 2020
